Clinical trial under way for topical AMD therapy

San Diego-TargeGen has begun a phase I trial of a topical drug to treat age-related macular degeneration (AMD).

The single-site, 45-patient study will test its small-molecule, multitargeted kinase inhibitor TG100801 as a therapy for AMD and other eye diseases.

The eye drop suppresses disease-related edema, angiogenesis, and inflammation. TargeGen expects to complete the phase I study by the end of the first quarter of 2007, with plans to start a phase II trial by mid-year.